Philip Tagari Appointed to CQDM’s Board of Directors


Partagez l'article

Montreal, October 5th, 2020 – Richard Fajzel, Chairman of CQDM’s Board of Directors and Diane Gosselin, President and CEO of CQDM are pleased to announce the appointment of Philip Tagari to the Board of Directors. Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc., one of the world’s leading biotechnology companies.

His impressive track record spans 35 years, including 20+ years at Amgen Inc. His work produced a major impact in the field of biopharmaceutical research, worldwide. Research labs under his direction have advanced over 30 innovative molecules to the clinical development stage in recent years. Prior to his tenure at Amgen, Philip was part of the Merck Frosst team in Montreal that discovered several important marketed medicines. Philip is a graduate of Cambridge University (UK), and performed research at Oxford and McGill Universities.

\”Mr. Tagari\’s world-class research expertise, particularly on drugs discovery, is undeniable: his contribution to our organization in the field of biopharmaceutical research will be extremely valuable,\” said Diane Gosselin. \”His extensive pharmaceutical experience will enhance our standing in the competitive life sciences environment,\” she adds.

\”CQDM\’s Board of Directors is comprised of bright, competent and well-connected people in the broad life sciences sector, both in terms of research and investment. By welcoming Philip Tagari and his expertise, our governance competencies will achieve heights we never imagined possible,\” said Richard Fajzel.

About CQDM

CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the discovery and development of drugs and vaccines. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. CQDM receives contributions from Quebec’s Ministry of Economy and Innovation (MEI), from large pharmaceutical companies, and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information: https://cqdm.orgen.


Contact for CQDM:

Philippe Viel
514 766-6661 # 2196

Scroll to Top